Total Payments
$323,920
2024 Payments
$90,348
Companies
25
Transactions
276
Medicare Patients
66
Medicare Billing
$9,331
Payment Breakdown by Category
Consulting$202,227 (62.4%)
Travel$64,350 (19.9%)
Research$29,131 (9.0%)
Other$23,514 (7.3%)
Food & Beverage$4,698 (1.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $202,227 | 89 | 62.4% |
| Travel and Lodging | $64,350 | 79 | 19.9% |
| Unspecified | $29,131 | 18 | 9.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $23,514 | 9 | 7.3% |
| Food and Beverage | $4,698 | 81 | 1.5% |
Payments by Type
General
$294,789
258 transactions
Research
$29,131
18 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $65,371 | 77 | $0 (2024) |
| Lilly USA, LLC | $53,535 | 23 | $0 (2024) |
| Biogen, Inc. | $49,244 | 35 | $0 (2024) |
| EISAI INC. | $39,512 | 29 | $0 (2022) |
| F. Hoffmann-La Roche AG | $21,443 | 22 | $0 (2024) |
| Novo Nordisk Inc | $21,339 | 18 | $0 (2024) |
| Merck Sharp & Dohme LLC | $11,677 | 10 | $0 (2024) |
| Avid Radiopharmaceuticals, Inc. | $9,106 | 6 | $0 (2020) |
| PFIZER INC. | $7,239 | 3 | $0 (2017) |
| Genentech, Inc. | $6,738 | 6 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $90,348 | 54 | Lilly USA, LLC ($53,513) |
| 2023 | $42,514 | 52 | Eli Lilly and Company ($15,825) |
| 2022 | $54,076 | 37 | Biogen, Inc. ($10,637) |
| 2021 | $13,410 | 9 | Eisai Inc. ($3,510) |
| 2020 | $29,923 | 23 | Biogen, Inc. ($15,485) |
| 2019 | $35,623 | 30 | Eli Lilly and Company ($11,351) |
| 2018 | $10,070 | 17 | Eli Lilly and Company ($3,180) |
| 2017 | $47,954 | 54 | Eisai Inc. ($16,426) |
All Payment Transactions
276 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $3,250.00 | General |
| 12/20/2024 | UCB SA | — | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| 12/20/2024 | UCB SA | — | Food and Beverage | Cash or cash equivalent | $183.52 | General |
| 12/20/2024 | UCB SA | — | Food and Beverage | Cash or cash equivalent | $12.31 | General |
| 11/25/2024 | Eli Lilly and Company | KISUNLA (Drug) | Consulting Fee | Cash or cash equivalent | $2,175.00 | General |
| Category: Neuroscience | ||||||
| 11/18/2024 | F. Hoffmann-La Roche AG | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $97.50 | General |
| 11/04/2024 | Lilly USA, LLC | KISUNLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,262.50 | General |
| Category: Neuroscience | ||||||
| 10/31/2024 | Lilly USA, LLC | KISUNLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,625.00 | General |
| Category: Neuroscience | ||||||
| 10/31/2024 | Lilly USA, LLC | — | Consulting Fee | Cash or cash equivalent | $4,712.50 | General |
| 10/28/2024 | UCB SA | — | Food and Beverage | In-kind items and services | $37.82 | General |
| 10/28/2024 | UCB SA | — | Food and Beverage | In-kind items and services | $10.26 | General |
| 10/24/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $6,942.11 | General |
| 10/24/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $6,882.40 | General |
| 10/24/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $348.20 | General |
| 10/24/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $270.70 | General |
| 10/24/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $107.50 | General |
| 10/24/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $99.50 | General |
| 10/24/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $96.29 | General |
| 09/25/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $4,650.00 | General |
| 09/18/2024 | Biogen, Inc. | — | Consulting Fee | Cash or cash equivalent | $988.75 | General |
| 08/02/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $3,900.00 | General |
| 07/30/2024 | Eli Lilly and Company | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $140.00 | General |
| Category: Neuroscience | ||||||
| 07/30/2024 | Eli Lilly and Company | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: Neuroscience | ||||||
| 07/27/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $4,485.00 | General |
| 07/27/2024 | F. Hoffmann-La Roche AG | — | Travel and Lodging | Cash or cash equivalent | $336.30 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $11,501 | 2 |
| 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease | Biogen, Inc. | $7,468 | 2 |
| A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects with Prodromal or Mild Alzheimer's Disease | Biogen, Inc. | $3,563 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $1,224 | 2 |
| GRADUATE I AND II: SAFETY RESULTS FROM TWO PHASE III TRIALS OF SUBCUTANEOUS GANTENERUMAB IN EARLY ALZHEIMERS DISEASE | F. Hoffmann-La Roche AG | $1,007 | 1 |
| ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE -A4 STUDY | Eli Lilly and Company | $810.00 | 2 |
| GRADUATE I and II: Revisiting the Key Findings From Two Phase III Studies Evaluating the Efficacy and Safety of Subcutaneous Gantenerumab in Early Alzheimers Disease | F. Hoffmann-La Roche AG | $760.48 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND DELAYED-START STUDY OF LY3314814 IN MILD ALZHEIMERS DISEASE DEMENTIA | Eli Lilly and Company | $691.65 | 1 |
| Gantenerumab in Early AD | F. Hoffmann-La Roche AG | $637.12 | 1 |
| GRADUATE I AND II: Results of Two Phase III Randomized Placebo-controlled Studies Assessing the Efficacy and Safety of Subcutaneous Gantenerumab in Early Alzheimers Disease | F. Hoffmann-La Roche AG | $385.83 | 1 |
| GRADUATE I AND II: Revisiting the key findings from two Phase III studies evaluating the efficacy and safety of subcutaneous gantenerumab in early Alzheimers disease (AD) | F. Hoffmann-La Roche AG | $350.50 | 1 |
| Amyloid-Related Imaging Abnormalities in Phase 3 Clinical Trials with Gantenerumab in Early Alzheimer?s Disease: Risk Factors Characteristics and Clinical Consequences | F. Hoffmann-La Roche AG | $301.28 | 1 |
| AN OPEN LABEL, MULTICENTER STUDY EVALUATING THE IMAGING CHARACTERISTICS OF A FOLLOW UP 18F-AV-1451 SCAN IN SUBJECTS THAT PARTICIPATED IN THE CONFIRMATORY COHORT OF 18F-AV-1451-A05 | Avid Radiopharmaceuticals, Inc. | $223.80 | 1 |
| PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | Genentech, Inc. | $207.50 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 1 | 39 | 39 | $19,068 | $5,876 |
| 2020 | 1 | 27 | 27 | $13,203 | $3,456 |
Total Patients
66
Total Services
66
Medicare Billing
$9,331
Procedure Codes
2
All Medicare Procedures & Services
2 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 39 | 39 | $19,068 | $5,876 | 30.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 27 | 27 | $13,203 | $3,456 | 26.2% |
About Dr. Stephen Salloway, MD
Dr. Stephen Salloway, MD is a Neurology healthcare provider based in Providence, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1891701116.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stephen Salloway, MD has received a total of $323,920 in payments from pharmaceutical and medical device companies, with $90,348 received in 2024. These payments were reported across 276 transactions from 25 companies. The most common payment nature is "Consulting Fee" ($202,227).
As a Medicare-enrolled provider, Salloway has provided services to 66 Medicare beneficiaries, totaling 66 services with total Medicare billing of $9,331. Data is available for 2 years (2020–2021), covering 2 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Providence, RI
- Active Since 07/31/2006
- Last Updated 08/15/2024
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1891701116
Products in Payments
- KISUNLA (Drug) $11,238
- ADUHELM (Biological) $9,270
- Non-Covered Product (Drug) $8,195
- None (Drug) $3,510
- ADLARITY (Drug) $2,240
- VIZAMYL (Drug) $1,250
- VRAYLAR (Drug) $186.95
- CNP520 (Drug) $180.63
- API015 (Drug) $25.45
- NAMZARIC (Drug) $22.49
- AMYVID (Drug) $21.81
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Providence
Syed Rizvi, Md, MD
Neurology — Payments: $482,996
Neurology $482,996
J Easton, Md, MD
Neurology — Payments: $274,886
Neurology $274,886
Jeffrey Wishik, Md, MD
Neurology — Payments: $46,542
Neurology $46,542
Dr. Karen Furie, Md, MD
Neurology — Payments: $31,250
Neurology $31,250
Dr. Chuang-Kuo Wu, M.d., Phd, M.D., PHD
Neurology — Payments: $27,531
Neurology $27,531
Joseph Friedman, Md, MD
Neurology — Payments: $18,203
Neurology $18,203